- recurring covid-19 patients. - subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent - receipt of convalescent covid-19 plasma, sars-cov-2 mab treatment, sars-cov-2 vaccine, or other investigational treatments prior to study entry.

- recurring covid-19 patients. - subjects with any unstable conditions, a history of significant hypersensitivity, or known allergy to components of the investigational agent - receipt of convalescent covid-19 plasma, sars-cov-2 mab treatment, sars-cov-2 vaccine, or other investigational treatments prior to study entry.